Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system.

Gagne JJ, Glynn RJ, Rassen JA, Walker AM, Daniel GW, Sridhar G, Schneeweiss S.

Clin Pharmacol Ther. 2012 Jul;92(1):80-6. doi: 10.1038/clpt.2011.369. Epub 2012 May 16.

2.

A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment.

Gagne JJ, Wang SV, Rassen JA, Schneeweiss S.

Pharmacoepidemiol Drug Saf. 2014 Jun;23(6):619-27. doi: 10.1002/pds.3616. Epub 2014 Apr 30.

3.

Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules.

Gagne JJ, Rassen JA, Walker AM, Glynn RJ, Schneeweiss S.

Epidemiology. 2012 Mar;23(2):238-46. doi: 10.1097/EDE.0b013e3182459d7d.

5.

A pharmacoepidemiological network model for drug safety surveillance: statins and rhabdomyolysis.

Reis BY, Olson KL, Tian L, Bohn RL, Brownstein JS, Park PJ, Cziraky MJ, Wilson MD, Mandl KD.

Drug Saf. 2012 May 1;35(5):395-406. doi: 10.2165/11596610-000000000-00000.

PMID:
22506565
6.

The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care.

García-Rodríguez LA, Massó-González EL, Wallander MA, Johansson S.

Pharmacoepidemiol Drug Saf. 2008 Oct;17(10):943-52. doi: 10.1002/pds.1603.

PMID:
18425988
7.

Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study.

Patel AM, Shariff S, Bailey DG, Juurlink DN, Gandhi S, Mamdani M, Gomes T, Fleet J, Hwang YJ, Garg AX.

Ann Intern Med. 2013 Jun 18;158(12):869-76. doi: 10.7326/0003-4819-158-12-201306180-00004.

PMID:
23778904
8.

"First-wave" bias when conducting active safety monitoring of newly marketed medications with outcome-indexed self-controlled designs.

Wang SV, Schneeweiss S, Maclure M, Gagne JJ.

Am J Epidemiol. 2014 Sep 15;180(6):636-44. doi: 10.1093/aje/kwu162. Epub 2014 Aug 1.

9.

The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases.

García-Rodríguez LA, González-Pérez A, Stang MR, Wallander MA, Johansson S.

Pharmacoepidemiol Drug Saf. 2008 Oct;17(10):953-61. doi: 10.1002/pds.1602.

PMID:
18425987
10.

The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis.

Alsheikh-Ali AA, Ambrose MS, Kuvin JT, Karas RH.

Circulation. 2005 Jun 14;111(23):3051-7. Epub 2005 May 23.

11.

Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.

McAdams M, Staffa J, Dal Pan G.

Pharmacoepidemiol Drug Saf. 2008 Mar;17(3):229-39. doi: 10.1002/pds.1535.

PMID:
18175291
12.

Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.

Chang JT, Staffa JA, Parks M, Green L.

Pharmacoepidemiol Drug Saf. 2004 Jul;13(7):417-26.

PMID:
15269925
13.

The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy.

McAfee AT, Ming EE, Seeger JD, Quinn SG, Ng EW, Danielson JD, Cutone JA, Fox JC, Walker AM.

Pharmacoepidemiol Drug Saf. 2006 Jul;15(7):444-53.

PMID:
16761308
14.

Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population.

Amend KL, Landon J, Thyagarajan V, Niemcryk S, McAfee A.

Ann Pharmacother. 2011 Oct;45(10):1230-9. doi: 10.1345/aph.1Q110. Epub 2011 Sep 13.

PMID:
21917557
15.

[Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].

Saito M, Hirata-Koizumi M, Miyake S, Hasegawa R.

Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku. 2005;(123):41-5. Japanese.

PMID:
16541751
16.

Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review.

Clay KD, Hanson JS, Pope SD, Rissmiller RW, Purdum PP 3rd, Banks PM.

Ann Intern Med. 2006 Mar 21;144(6):415-20. Epub 2006 Feb 15. Review.

PMID:
16481451
17.

Rosuvastatin safety: lessons from the FDA review and post-approval surveillance.

Davidson MH.

Expert Opin Drug Saf. 2004 Nov;3(6):547-57. Review.

PMID:
15500414
18.

Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction.

Strandell J, Bate A, Hägg S, Edwards IR.

Br J Clin Pharmacol. 2009 Sep;68(3):427-34. doi: 10.1111/j.1365-2125.2009.03473.x.

19.

Statin safety.

Foxton J.

Nurs Stand. 2001 Sep 19-25;16(1):20. No abstract available.

PMID:
11977679
20.

Telithromycin use and spontaneous reports of hepatotoxicity.

Dore DD, DiBello JR, Lapane KL.

Drug Saf. 2007;30(8):697-703.

PMID:
17696582
Items per page

Supplemental Content

Write to the Help Desk